Alpha-Synuclein Targeting for Parkinson's Disease

I know this is still a topic of much debate whether or not targeting alpha-synuclein is going to be fruitful. Can you comment on these monoclonal antibody treatments for Parkinson's? This is something that should still be looked into, or are you in the camp that this is unlikely to be effective with regards to disease modification? As you said, there's two camps, and I'm sort of halfway in between. One camp says, well, how many negative trials do we need before we bin the whole idea of anti-alpha- synuclein treatments? That's one way to go.